Alza's OROS delivery system
Executive Summary
Firm announced on June 19 that its oral osmotic technology will be applied to Glaxo's Ventolin (albuterol) bronchodilator and to Pfizer's Minipress (prazosin) antihypertensive, under joint development agreements with the two pharmaceutical mfrs. Glaxo and Pfizer will make and market the controlled release formulations under a royalty-bearing license from Alza. Pfizer has a similar agreement for an OROS version of the calcium channel blocker Procardia (nifedipine).